The adjunctive use of topical corticosteroids and/or corneal cross-linking (CXL) with riboflavin in the treatment of bacterial keratitis have long been debated.1-4 The recent Steroids and Cross-Linking Ulcer Treatment Trial II (SCUT II) trial primary outcome revealed no benefit or harm of adjunctive corticosteroids at 6 months in terms of best spectacle-corrected visual acuity (BSCVA) and infiltrate and/or scar size; CXL offered no benefit in BSCVA and resulted in increased scar size at 6...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile